← Back to all signals
RESEARCH PAPER ANALYSIS

Disrupted Structural and Metabolic Brain Networks with Structural - Metabolic Decoupling in Parkinson's Disease: An Integrated PET/MRI Study.

Using integrated 18F-FDG PET and DTI in 43 Parkinson's patients versus 25 controls, the study found preserved small-world topology but reduced metabolic network integration and significant regional decoupling between structural and metabolic connectivity—most prominently in orbitofrontal-basal…

PMID42020229
JournalAcademic radiology
Publication Date2026-04-21
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

Using integrated 18F-FDG PET and DTI in 43 Parkinson's patients versus 25 controls, the study found preserved small-world topology but reduced metabolic network integration and significant regional decoupling between structural and metabolic connectivity—most prominently in orbitofrontal-basal…

WHY IT MATTERS

Research significance

By revealing network-level structural–metabolic decoupling, especially in orbitofrontal–basal ganglia circuits, the work suggests multimodal imaging biomarkers for patient stratification and for tracking or targeting circuit- and metabolism-focused interventions, though it stops short of…

ABSTRACT

Source abstract

RATIONALE AND OBJECTIVES: Recent brain network studies have been broadly applied in Parkinson's disease (PD), but the relationship between structural and metabolic networks remains unclear. This study aimed to use integrated PET/MRI to investigate whether decoupling exists between structural and metabolic networks in the brains of PD patients, providing imaging evidence to elucidate the mechanisms of network disruption in PD. MATERIALS AND METHODS: We collected diffusion tensor imaging (DTI) data and 18F-FDG PET imaging data and from 43 patients with PD and 25 healthy controls (HC), generated structural connectivity (SC) and metabolic connectivity (MC) networks. Graph-theoretical methods were used to characterize the topological properties of networks. Based on Yeo 7-network parcellation, whole brain was divided into 7 functional modules, and the structural-metabolic connectivity (SC-MC) coupling was compared at both regional and module level. RESULTS: Both SC and MC networks of PD patients retained small-world properties. For global topological properties, MC network showed longer characteristic path length (Lp) and lower global efficiency (Eg), whereas SC network did not differ from controls. At whole-brain level, compared with HC, significant SC-MC decoupling in bilateral orbital inferior frontal gyrus (IFGorb), bilateral orbital middle frontal gyrus (MFGorb) and right pallidum (PG) (all with pFDR < 0.001) was showed in PD patients. At module level, stronger SC-MC coupling of somatomotor network (SMN) (pFDR = 0.04) was found in PD patients. However, visual network (VIS) (pFDR < 0.001), ventral attention network (VAN) (pFDR = 0.019) and frontoparietal control network (FPCN) (pFDR = 0.027) showed significant SC-MC decoupling in PD patients. CONCLUSION: Our results showed that PD is associated with reduced metabolic network integration and regional SC-MC decoupling, with the most prominent effects located in orbitofrontal-basal ganglia circuits. SC-MC may provide information complementary to SC-functional connectivity (FC) and shows promise as a multimodal, network-level biomarker.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic